Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity

Dermatology Online Journal

Volumn 19, Issue 4, 2013, Pages

  Maldonado Seral, Cayetana ^a   Berros Fombella, Jose Pablo ^a   Vivanco Allende, Blanca ^a   Coto Segura, Pablo ^a   Vazquez Lopez, Francisco ^a   Perez Oliva, Narciso ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TUMOR PROTEIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ASSOCIATION; EYELID CARCINOMA; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MELANOMA; PANNICULITIS; SKIN BIOPSY; SKIN NODULE; SKIN SURGERY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; EYELID TUMOR; GENETICS; LUNG TUMOR; METASTASIS; NEUTROPHIL; PATHOLOGY; REVIEW; SECOND CANCER; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; SECONDARY;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; EYELID NEOPLASMS; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; NEUTROPHILS; PANNICULITIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84876213762     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366:707-714. [PubMed]
2. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364:2507-2516. [PubMed]
3. Zimmer L, Livingstone E, Hillen U et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012; 148:357-361. [PubMed]
4. Monfort JB, Pages C, Schneider P et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res. 2012;22:399-401. [PubMed]
5. Chen AP, Setser A, Anadkat MJ et al. Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events 4.0. J Am Acad Dermatol 2012; 67(5):1025-1039. [PubMed]
6. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway. Arch Dermatol. 2012; 148:628-633. [PubMed]
7. Chu EY, Wanat KA, Miller CJ et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol. 2012. May 18 [Epub ahead of print]. [PubMed]
8. Wang CM, Fleming KF, Hsu S. A case of vemurafenib-induced keratosis pilaris-like eruption. Dermatol Online J. 2012; 18:7. [PubMed]
9. Sinha R, Edmonds K, Newton-Bishop JA et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advine on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167:987-994. [PubMed].